TMAC�: A novel Affimer® drug conjugate platform to modulate the TME.

The Affimer platform is an antibody mimetic scaffold based on the human protease inhibitor, Stefin A and we have generated a range of antagonists against several key checkpoints such PD-L1. With our anti-PDL1 Affimer Fc we have demonstrated total tumour regression in mouse syngeneic models in combination with Talabostat and immunity to rechallenge with tumour cells, showing that we have achieved an immune memory response. Conjugating Talabostat to an Affimer antagonist using a novel FAP-alpha cleavable linker (TMAC™), we have demonstrated tolerability and efficacy in mouse syngeneic models.

Author(s): : Amrik Basran

Abstract | PDF

Share This Article